Search results for Fbnrx

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

Forte Biosciences: Targeting Celiac Disease

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

FGN And FGSN: F&G Annuities' 2 Long-Dated Notes - The Second Has A Buy Rating

FBDC: Actively Managed BDC Exposure

Obsidian, Galera to advance cell therapy following reverse merger

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement expected to deliver $350 million in gross proceeds.

argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System

Next Big Crypto Compared: BlockchainFX (BFX) vs NOCtura (NOC) vs IPO Genie (IPO) in 2026

BlockchainFX leads the 2026 presale race with $14.43M raised, CEX60 bonus tokens, and stronger traction than NOCtura and IPO Genie.

Bicara (BCAX) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DateMay 11, 2026, at 8:30 a.m. ETCall participantsChief Executive Officer — Claire Mazumdar ClemonChief Medical Officer — Bill SchelmanChief Commerc...

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch

Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.

New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Pe...

Sponsored Programming Supported by Commercials from Medicus Pharma (NASDAQ:MDCX), IGC Pharma (NYSE American:IGC), Roadzen (NASDAQ:RDZN), and Lantern Pharma (NASDAQ:LTRN)

FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111

FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111

Fabege AB (publ) (FBGBY) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

GRS Advisors Opens $49 Million Broadstone Net Lease Position, According to Recent SEC Filing

Broadstone Net Lease has the steady rent base investors expect from long-term tenant contracts. The next question is whether new property investments can turn that stability into p...

Beta Bionics BBNX Q1 2026 Earnings Transcript

Image source: The Motley Fool. DateTuesday, April 21, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Sean SaintChief Financial Officer — Stephen FeiderHead of Inve...

Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day - Slideshow

Protalix: Elfabrio Struggles Against Oral Competition

First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20